ARWR says ploza(s)iran robust in Phase 3 sHTG trial
ARWR says ploza(s)iran showed robust efficacy and safety in Phase 3 sHTG trials, supporting global regulatory filings.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ARWR says ploza(s)iran showed robust efficacy and safety in Phase 3 sHTG trials, supporting global regulatory filings.